Detalles de la búsqueda
1.
Purinylpyridinylamino-based DFG-in/αC-helix-out B-Raf inhibitors: Applying mutant versus wild-type B-Raf selectivity indices for compound profiling.
Bioorg Med Chem
; 24(10): 2215-34, 2016 05 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-27085672
2.
Corrigendum to "Purinylpyridinylamino-based DFG-in/αC-helix-out B-Raf inhibitors: Applying mutant versus wild-type B-Raf selectivity indices for compound profiling" [Bioorg. Med. Chem. 24 (2016) 2215-2234].
Bioorg Med Chem
; 24(13): 3093, 2016 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27234892
3.
Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity.
J Med Chem
; 60(14): 5990-6017, 2017 07 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-28324649
4.
Discovery of (R)-6-(1-(8-Fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one (AMG 337), a Potent and Selective Inhibitor of MET with High Unbound Target Coverage and Robust In Vivo Antitumor Activity.
J Med Chem
; 59(6): 2328-42, 2016 Mar 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-26812066
5.
Discovery of potent and selective 8-fluorotriazolopyridine c-Met inhibitors.
J Med Chem
; 58(5): 2417-30, 2015 Mar 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-25699405
6.
Discovery of N-(4-(3-(2-aminopyrimidin-4-yl)pyridin-2-yloxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine (AMG 900), a highly selective, orally bioavailable inhibitor of aurora kinases with activity against multidrug-resistant cancer cell lines.
J Med Chem
; 58(13): 5189-207, 2015 Jul 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-25970324
7.
Correction to Discovery of Potent and Selective 8-Fluorotriazolopyridine c-Met Inhibitors.
J Med Chem
; 58(9): 4087, 2015 May 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-25901648
Resultados
1 -
7
de 7
1
Próxima >
>>